{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:57:57Z","timestamp":1791136677752,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,4,21]],"date-time":"2012-04-21T00:00:00Z","timestamp":1334966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1245\/s10434-012-2358-7","type":"journal-article","created":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T12:03:18Z","timestamp":1334923398000},"page":"2643-2651","source":"Crossref","is-referenced-by-count":62,"title":["Resection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified?"],"prefix":"10.1245","volume":"19","author":[{"given":"S\u00e9bastien","family":"Gaujoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"Gonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinru","family":"Shia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"D\u2019Angelica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Dematteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Blumgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,21]]},"reference":[{"issue":"6","key":"2358_CR1","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1210\/jc.2008-2291","volume":"94","author":"SH Golden","year":"2009","unstructured":"Golden SH, Robinson KA, Saldanha I, et al. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94(6):1853\u201378.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2358_CR2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115(2):243\u201350.","journal-title":"Cancer."},{"issue":"11","key":"2358_CR3","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","volume":"113","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113(11):3130\u20136.","journal-title":"Cancer."},{"issue":"5","key":"2358_CR4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","volume":"30","author":"E Kebebew","year":"2006","unstructured":"Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30(5):872\u20138.","journal-title":"World J Surg."},{"key":"2358_CR5","doi-asserted-by":"crossref","unstructured":"Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006.","DOI":"10.1210\/jc.2005-2730"},{"issue":"7","key":"2358_CR6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00268-001-0047-y","volume":"25","author":"P Icard","year":"2001","unstructured":"Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg. 2001;25(7):891\u20137.","journal-title":"World J Surg."},{"issue":"1","key":"2358_CR7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2006-0706","volume":"92","author":"G Assie","year":"2007","unstructured":"Assie G, Antoni G, Tissier F, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2007;92(1):148\u201354.","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2358_CR8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10434-999-0719-7","volume":"6","author":"RD Schulick","year":"1999","unstructured":"Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6(8):719\u201326.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"2358_CR9","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0039-6060(97)90229-4","volume":"122","author":"R Bellantone","year":"1997","unstructured":"Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122(6):1212\u20138.","journal-title":"Surgery."},{"issue":"2","key":"2358_CR10","first-page":"R15","volume":"18","author":"B Ragazzon","year":"2011","unstructured":"Ragazzon B, Assie G, Bertherat J. Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocr Relat Cancer. 2011;18(2):R15\u201327.","journal-title":"Endocr Relat Cancer."},{"issue":"2","key":"2358_CR11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/1078-0432.CCR-10-2006","volume":"17","author":"S Gaujoux","year":"2011","unstructured":"Gaujoux S, Grabar S, Fassnacht M, et al. beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res. 2011;17(2):328\u201336.","journal-title":"Clin Cancer Res."},{"issue":"21","key":"2358_CR12","doi-asserted-by":"crossref","first-page":"8276","DOI":"10.1158\/0008-5472.CAN-10-2014","volume":"70","author":"B Ragazzon","year":"2010","unstructured":"Ragazzon B, Libe R, Gaujoux S, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010;70(21):8276\u201381.","journal-title":"Cancer Res."},{"issue":"6","key":"2358_CR13","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1210\/jc.78.6.1444","volume":"78","author":"C Gicquel","year":"1994","unstructured":"Gicquel C, Bertagna X, Schneid H, et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 1994;78(6):1444\u201353.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2358_CR14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1078-0432.CCR-06-2085","volume":"13","author":"R Libe","year":"2007","unstructured":"Libe R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res. 2007;13(3):844\u201350.","journal-title":"Clin Cancer Res."},{"issue":"24","key":"2358_CR15","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1200\/JCO.2005.04.096","volume":"23","author":"JL Westra","year":"2005","unstructured":"Westra JL, Schaapveld M, Hollema H, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23(24):5635\u201343.","journal-title":"J Clin Oncol."},{"issue":"4","key":"2358_CR16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ejca.2009.12.007","volume":"46","author":"G Lughezzani","year":"2010","unstructured":"Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46(4):713\u20139.","journal-title":"Eur J Cancer."},{"issue":"4","key":"2358_CR17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1200\/JCO.20.4.941","volume":"20","author":"A Stojadinovic","year":"2002","unstructured":"Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20(4):941\u201350.","journal-title":"J Clin Oncol."},{"issue":"12","key":"2358_CR18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/0895-4356(95)00510-2","volume":"48","author":"J Concato","year":"1995","unstructured":"Concato J, Peduzzi P, Holford TR, et al. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol. 1995;48(12):1495\u2013501.","journal-title":"J Clin Epidemiol."},{"key":"2358_CR19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/00401706.1974.10489231","volume":"16","author":"GM Furnival","year":"1974","unstructured":"Furnival GM, Wilson RW. Regression by leaps and bounds. Technometrics. 1974;16:499\u2013511.","journal-title":"Technometrics."},{"issue":"4","key":"2358_CR20","first-page":"524","volume":"244","author":"R Adam","year":"2006","unstructured":"Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244(4):524\u201335.","journal-title":"Ann Surg."},{"key":"2358_CR21","doi-asserted-by":"crossref","unstructured":"Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2009.","DOI":"10.1016\/j.ejca.2009.12.007"},{"issue":"6","key":"2358_CR22","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2005-2639","volume":"91","author":"B Allolio","year":"2006","unstructured":"Allolio B, Fassnacht M. Clinical review. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2027\u201337.","journal-title":"J Clin Endocrinol Metab."},{"issue":"27","key":"2358_CR23","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1200\/JCO.2008.17.2775","volume":"27","author":"I Veytsman","year":"2009","unstructured":"Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27(27):4619\u201329.","journal-title":"J Clin Oncol."},{"issue":"1","key":"2358_CR24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1245\/s10434-009-0716-x","volume":"17","author":"EG Grubbs","year":"2010","unstructured":"Grubbs EG, Callender GG, Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17(1):263\u201370.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"2358_CR25","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/cncr.10487","volume":"94","author":"J Abraham","year":"2002","unstructured":"Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a p-glycoprotein antagonist. Cancer. 2002;94(9):2333\u201343.","journal-title":"Cancer."},{"key":"2358_CR26","doi-asserted-by":"crossref","unstructured":"Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p\u2019DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 2000;11(10):1281\u20137.","DOI":"10.1023\/A:1008377915129"},{"issue":"5","key":"2358_CR27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R","volume":"88","author":"SK Williamson","year":"2000","unstructured":"Williamson SK, Lew D, Miller GJ, et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group study. Cancer. 2000;88(5):1159\u201365.","journal-title":"Cancer."},{"issue":"3","key":"2358_CR28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.11084","volume":"97","author":"BJ Wood","year":"2003","unstructured":"Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003;97(3):554\u201360.","journal-title":"Cancer."},{"issue":"7","key":"2358_CR29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-0028-1087178","volume":"117","author":"J Bauditz","year":"2009","unstructured":"Bauditz J, Quinkler M, Wermke W. Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer\u2013a case report and review of the literature. Exp Clin Endocrinol Diabetes. 2009;117(7):316\u20139.","journal-title":"Exp Clin Endocrinol Diabetes."},{"issue":"2","key":"2358_CR30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1148\/radiol.2402050807","volume":"240","author":"T Baere de","year":"2006","unstructured":"de Baere T, Palussiere J, Auperin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1\u00a0year: prospective evaluation. Radiology. 2006;240(2):587\u201396.","journal-title":"Radiology."},{"issue":"4","key":"2358_CR31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-133-4-200008150-00028","volume":"133","author":"J Abraham","year":"2000","unstructured":"Abraham J, Fojo T, Wood BJ. Radiofrequency ablation of metastatic lesions in adrenocortical cancer. Ann Intern Med. 2000;133(4):312\u20133.","journal-title":"Ann Intern Med."},{"issue":"7","key":"2358_CR32","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1245\/s10434-011-1564-z","volume":"18","author":"RT Ripley","year":"2011","unstructured":"Ripley RT, Kemp CD, Davis JL, et al. Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol. 2011;18(7):1972\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"2358_CR33","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jvir.2010.05.020","volume":"21","author":"J Cazejust","year":"2010","unstructured":"Cazejust J, De Baere T, Auperin A, et al. Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol. 2010;21(10):1527\u201332.","journal-title":"J Vasc Interv Radiol."},{"issue":"2","key":"2358_CR34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/13651820500471848","volume":"8","author":"I Carlo Di","year":"2006","unstructured":"Di Carlo I, Toro A, Sparatore F, et al. Liver resection for hepatic metastases from adrenocortical carcinoma. HPB (Oxford). 2006;8(2):106\u20139.","journal-title":"HPB (Oxford)."},{"issue":"2","key":"2358_CR35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/01.sla.0000150244.72285.ad","volume":"241","author":"J Weitz","year":"2005","unstructured":"Weitz J, Blumgart LH, Fong Y, et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg. 2005;241(2):269\u201376.","journal-title":"Ann Surg."},{"issue":"3","key":"2358_CR36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1677\/erc.1.01029","volume":"12","author":"DE Schteingart","year":"2005","unstructured":"Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12(3):667\u201380.","journal-title":"Endocr Relat Cancer."},{"issue":"3","key":"2358_CR37","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","volume":"12","author":"A Berruti","year":"2005","unstructured":"Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12(3):657\u201366.","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2358_CR38","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/BF02067377","volume":"16","author":"P Icard","year":"1992","unstructured":"Icard P, Louvel A, Chapuis Y. Survival rates and prognostic factors in adrenocortical carcinoma. World J Surg. 1992;16(4):753\u20138.","journal-title":"World J Surg."},{"issue":"2","key":"2358_CR39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0039-6060(96)80164-4","volume":"119","author":"F Crucitti","year":"1996","unstructured":"Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multi-institutional series of 129 patients. The ACC Italian Registry Study Group. Surgery. 1996;119(2):161\u201370.","journal-title":"Surgery."},{"issue":"6","key":"2358_CR40","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/01.sla.0000246847.02058.1b","volume":"244","author":"R Adam","year":"2006","unstructured":"Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244(6):897\u2013908.","journal-title":"Ann Surg."},{"issue":"6","key":"2358_CR41","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/01.sla.0000145964.08365.01","volume":"240","author":"R Adam","year":"2004","unstructured":"Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6):1052\u201361; discussion 1061\u20134.","journal-title":"Ann Surg."},{"issue":"6","key":"2358_CR42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.surg.2007.09.006","volume":"142","author":"RJ Gonzalez","year":"2007","unstructured":"Gonzalez RJ, Tamm EP, Ng C, et al. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery. 2007;142(6):867\u201374.","journal-title":"Surgery."},{"key":"2358_CR43","doi-asserted-by":"crossref","unstructured":"Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol. 2010;28(23):e401\u20132; author reply e403.","DOI":"10.1200\/JCO.2009.27.5958"},{"issue":"23","key":"2358_CR44","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"M Terzolo","year":"2007","unstructured":"Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372\u201380.","journal-title":"N Engl J Med."},{"issue":"1","key":"2358_CR45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/jc.2005-1739","volume":"91","author":"LS Kirschner","year":"2006","unstructured":"Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab. 2006;91(1):14\u201321.","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2358_CR46","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1210\/jc.2008-0247","volume":"93","author":"M Doghman","year":"2008","unstructured":"Doghman M, Cazareth J, Lalli E. The T cell factor\/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab. 2008;93(8):3222\u20135.","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2358_CR47","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2174\/138945010792006780","volume":"11","author":"JR Prosperi","year":"2010","unstructured":"Prosperi JR, Goss KH. A Wnt-ow of opportunity: targeting the Wnt\/beta-catenin pathway in breast cancer. Curr Drug Targets. 2010;11(9):1074\u201388.","journal-title":"Curr Drug Targets."},{"issue":"10","key":"2358_CR48","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1210\/jc.2008-0631","volume":"93","author":"S Gaujoux","year":"2008","unstructured":"Gaujoux S, Tissier F, Groussin L, et al. Wnt\/beta-catenin and 3\u2032,5\u2032-cyclic adenosine 5\u2032-monophosphate\/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab. 2008;93(10):4135\u201340.","journal-title":"J Clin Endocrinol Metab."},{"key":"2358_CR49","doi-asserted-by":"crossref","unstructured":"Ragazzon B, Libe R, Gaujoux S, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010.","DOI":"10.1158\/0008-5472.CAN-10-2014"},{"issue":"2","key":"2358_CR50","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/(SICI)1096-9896(199702)181:2<146::AID-PATH744>3.0.CO;2-7","volume":"181","author":"AM McNicol","year":"1997","unstructured":"McNicol AM, Nolan CE, Struthers AJ, et al. Expression of p53 in adrenocortical tumours: clinicopathological correlations. J Pathol. 1997;181(2):146\u201352.","journal-title":"J Pathol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-012-2358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-012-2358-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-012-2358-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T11:47:15Z","timestamp":1572954435000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-012-2358-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,21]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["2358"],"URL":"https:\/\/doi.org\/10.1245\/s10434-012-2358-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,21]]}}}